- ICH GCP
- Register voor klinische proeven in de VS.
- Klinische proef NCT00327197
Assessment Of Disease Pathology And Key Therapeutic Targets In Severe Asthma
A Study to Assess Disease Pathology and Key Therapeutic Targets in Severe Asthma
To evaluate and compare the expression and change in expression of key severe asthma targets at baseline in mile to moderate asthmatics vs. severe asthmatic subjects.
To evaluate and compare the airway pathology at baseline and changes in airway pathology in relation to asthma severity.
Studie Overzicht
Toestand
Conditie
Interventie / Behandeling
Studietype
Inschrijving (Werkelijk)
Fase
- Fase 1
Contacten en locaties
Studie Locaties
-
-
Leicestershire
-
Leicester, Leicestershire, Verenigd Koninkrijk, LE3 9QP
- GSK Investigational Site
-
-
Deelname Criteria
Geschiktheidscriteria
Leeftijden die in aanmerking komen voor studie
Accepteert gezonde vrijwilligers
Geslachten die in aanmerking komen voor studie
Beschrijving
Inclusion criteria:
- History of asthma with exclusion of other significant pulmonary disease.
- Body Mass Index between 19-31 kg.m-2.
- Subjects will be assigned to group 1(mild to moderate) or Group 2 (severe asthmatics) depending on their Lung Function test results.
Exclusion criteria:
- As a result of medical interview, physical examination or screening investigation the physician responsible considers the subject unfit for the study.
- History of drug or other allergy, which, in the opinion of the responsible physician, contra-indicates their participation.
- Subject is female who is pregnant or lactating.
- Currently or planning to take during the study regular medication (including over-the-counter) except for medication allowed in inclusion criteria.
- Having participated within 30 days or 5 half-lives, whichever is longer of the first dose in a study using new molecular entity, or the first dose in any other study investigating drugs or having participated within one month of the first dose in a study with invasive procedures.
- History or current evidence of an upper or lower respiratory infection or symptoms (including common cold) within 2 weeks of baseline assessments.
- History of abnormal bruising or bleeding.
- History of alcohol or drug abuse.
- Doing night-shift work within at least 5 days prior to dosing until completion of the study.
- Anticoagulants except low dose of Aspirin (80 mg per day) (for bronchoscopy).
- Beta blockers except for low dose Atenolol (25 mg/day) or Metoprolol (50 mg/day) (for bronchoscopy).
- Use of Cytochrome P450 inhibitors.
- History of hypersensitivity to any of the following medications: Lidocaine, Fentanyl, Versed, Demerol, Midazolam, Epinephrine, Flumazenil and Naloxone.
- History of hypersensitivity to bronchodilator (such as Albuterol).
In addition, the following additional exclusion criteria must apply to mild to moderate persistent asthmatics on regular inhaled steroids:
- Changed asthma medication within the 4 weeks prior to screening.
- Has had an asthma exacerbation in the previous month.
- Known sensitivity or allergy to prednisolone.
- Current use or use within the previous 3 months of oral corticosteroids.
- Current use of Methotrexate, cyclosporine and PDE inhibitors
- History of tuberculosis, diabetes mellitus, osteoporosis, severe hypertension, glaucoma , severe affective disorder and peptic ulceration.
In addition, the following additional exclusion criteria must apply to severe persistent asthmatics with clinical controlled asthma symptoms:
- Changed asthma medication within the 4 weeks prior to screening.
- Has had an asthma exacerbation in the previous month.
- sensitivity or allergy to prednisolone.
- History of tuberculosis, diabetes mellitus, osteoporosis, hypertension, glaucoma, severe affective disorder and peptic ulceration.
- Current use or use within the previous 4 weeks of oral prednisolone or equivalent of greater than 20mg daily.
- Current use of Methotrexate, cyclosporin.
Studie plan
Hoe is de studie opgezet?
Ontwerpdetails
- Primair doel: Behandeling
- Toewijzing: Gerandomiseerd
- Interventioneel model: Parallelle opdracht
- Masker: Geen (open label)
Wapens en interventies
Deelnemersgroep / Arm |
Interventie / Behandeling |
|---|---|
|
Experimenteel: Intermittent mild steroid-naïve asthmatic group
Asymptomatic subjects receiving only beta-agonist inhaler with predicted FEV1 >=80% and normal peak expiratory flow between attacks will be included.
|
Subjects will be administered oral prednisolone at a dose of 0.5 mg/kg, up to a maximum of 40 mg per day for 14 days.
All subjects will undergo bronchoscopy assessments which will involve insertion of a standard bronchoscope.
|
|
Experimenteel: Mild to moderate persistent asthmatic group
Subjects with mild to moderate persistent asthma on low to moderate dose of inhaled corticosteroid (200-500 microgram fluticasone propionate daily or equivalent), an FEV1 >= 80% predicted (post-bronchodilator), and less than 20% variability in peak expiratory flow.
|
Subjects will be administered oral prednisolone at a dose of 0.5 mg/kg, up to a maximum of 40 mg per day for 14 days.
All subjects will undergo bronchoscopy assessments which will involve insertion of a standard bronchoscope.
|
|
Experimenteel: Severe asthma group
Subjects with severe persistent asthma.
They will be on either: high inhaled corticosteroid (CS >=1000 microgram fluticasone daily or equivalent) or on high dose inhaled CS plus oral CS (no more than 20 milligrams predisolone a day).
The subjects should have at least one ( if on oral steroids) or two (if only on inhaled steroids) of the following: 1) FEV1<80% and FEV1/FVC ratio <70% 2) more than 25% variability in peak expiratory flow 3) daily symptoms ± nocturnal symptoms 4) severe exacerbations of >= twice a year in at least one of the last two years.
|
Subjects will be administered oral prednisolone at a dose of 0.5 mg/kg, up to a maximum of 40 mg per day for 14 days.
All subjects will undergo bronchoscopy assessments which will involve insertion of a standard bronchoscope.
|
|
Placebo-vergelijker: Healthy subjects group
Non-asthmatic and non-smokers with FEV1 > 85% predicted, on no regular medication.
|
All subjects will undergo bronchoscopy assessments which will involve insertion of a standard bronchoscope.
|
Wat meet het onderzoek?
Primaire uitkomstmaten
Uitkomstmaat |
Maatregel Beschrijving |
Tijdsspanne |
|---|---|---|
|
Airway pathology endpoints Target Validation endpoints Biomarker endpoints Clinical endpoints
Tijdsspanne: Through 2 weeks of Prednisolone dosing
|
biomarkers, vital signs, ECG
|
Through 2 weeks of Prednisolone dosing
|
Secundaire uitkomstmaten
Uitkomstmaat |
Maatregel Beschrijving |
Tijdsspanne |
|---|---|---|
|
Expression of airway and systemic biomarkers. Relationship between changes in target expression and clinical measures of disease activity. Relationship between steady state plasma exposure of prednisolone and pharmacodynamic biomarkers.
Tijdsspanne: Through 2 weeks of prednisolone dosing.
|
biomarkers
|
Through 2 weeks of prednisolone dosing.
|
Medewerkers en onderzoekers
Sponsor
Publicaties en nuttige links
Studie record data
Bestudeer belangrijke data
Studie start (Werkelijk)
Primaire voltooiing (Werkelijk)
Studie voltooiing (Werkelijk)
Studieregistratiedata
Eerst ingediend
Eerst ingediend dat voldeed aan de QC-criteria
Eerst geplaatst (Schatting)
Updates van studierecords
Laatste update geplaatst (Werkelijk)
Laatste update ingediend die voldeed aan QC-criteria
Laatst geverifieerd
Meer informatie
Termen gerelateerd aan deze studie
Trefwoorden
Aanvullende relevante MeSH-voorwaarden
- Ziekten van de luchtwegen
- Ziekten van het immuunsysteem
- Longziekten
- Overgevoeligheid, Onmiddellijk
- Bronchiale ziekten
- Longziekten, obstructief
- Ademhalingsovergevoeligheid
- Overgevoeligheid
- Astma
- Fysiologische effecten van medicijnen
- Ontstekingsremmende middelen
- Antineoplastische middelen
- Glucocorticoïden
- Hormonen
- Hormonen, hormoonvervangers en hormoonantagonisten
- Antineoplastische middelen, hormonaal
- Prednisolon
Andere studie-ID-nummers
- RES100769
Deze informatie is zonder wijzigingen rechtstreeks van de website clinicaltrials.gov gehaald. Als u verzoeken heeft om uw onderzoeksgegevens te wijzigen, te verwijderen of bij te werken, neem dan contact op met register@clinicaltrials.gov. Zodra er een wijziging wordt doorgevoerd op clinicaltrials.gov, wordt deze ook automatisch bijgewerkt op onze website .